RXC004 Phase 1 monotherapy data to be presented at ESMO Congress 2021Redx Pharma Announces Milestone Payment from Jazz PharmaceuticalsRedx Pharma Announces Phase 2 Dose Selection of its Porcupine Inhibitor, RXC004

Top suggestions

News & events

Featured

Press Release

02-Sep-2021

Redx Pharma Announces Milestone Payment from Jazz Pharmaceuticals

PDF

27-Jul-2021

Redx Pharma Announces Phase 2 Dose Selection of its Porcupine Inhibitor, RXC004

PDF

Press releases & media coverage

Filter by

Press release Media coverage Analyst reports
Programme Key External Link PDF

13-Sep-2021

RXC004 Phase 1 monotherapy data to be presented at ESMO Congress 2021

Press release

02-Sep-2021

Redx Pharma Announces Milestone Payment from Jazz Pharmaceuticals

Press release

27-Jul-2021

Redx Pharma Announces Phase 2 Dose Selection of its Porcupine Inhibitor, RXC004

Press release

08-Jul-2021

Exercise of Options and Total Voting Rights

Press release

17-Jun-2021

Redx to Receive Milestone Payment of $4 million for RXC006

Press release

08-Jun-2021

New Trinity Delta Research Report Published

Analyst reports

07-Jun-2021

Interim results for the six months ended 31 March

Press release

04-Jun-2021

Change of Auditor

Press release

03-Jun-2021

First Subject Dosed in Phase 1 Study with RXC007

Press release

01-Jun-2021

Directorate Change

Press release

24-May-2021

Notice of Interim Results

Press release

19-May-2021

Appointment of Non-Executive Director

Press release

05-May-2021

Appointment of Peter Collum, as Chief Financial Officer

Press release

29-Apr-2021

Redx Pharma begin phase I trial to discover potential of its cancer drug as a combination therapy (proactiveinvestors.co.uk)

Media coverage

28-Apr-2021

Dosing of first patients with RXC004 and Anti-PD1

Press release

29-Mar-2021

Redx Pharma to present at the American Association for Cancer Research Annual Meeting

Press release

15-Mar-2021

Appointment of Joint Broker

Press release

11-Mar-2021

Lisa Anson discusses life science funding and investment with Pharmaphorum (Podcast)

Media coverage

11-Mar-2021

Result of AGM and Directorate change

Press release

11-Mar-2021

New Grant of Options

Press release

25-Feb-2021

Redx Pharma to present at the Cowen 41st Annual Health Care Conference

Media coverage

05-Feb-2021

Notice of Annual General Meeting

Press release

28-Jan-2021

New Trinity Delta Research Report Published

Analyst reports

27-Jan-2021

Final Results for the Year Ended 30 September 2020

Press release

21-Dec-2020

Results of Open Offer and General Meeting

Press release

07-Dec-2020

CEO Lisa Anson discussed £25.5m raise to drive forward key programmes

Media coverage

02-Dec-2020

Placing and Open Offer Announcement

Press release

02-Dec-2020

New Trinity Delta Research Report Published

Analyst reports

02-Dec-2020

New Grant of Options

Press release

02-Nov-2020

Lisa talks through our strategy at the Proactive One2One Virtual Biotech Forum 29th October

Media coverage

27-Oct-2020

Redx Announces Appointment of Chief Medical Officer

Press release

07-Oct-2020

Interview with Lisa Anson in The Sunday Times

Media coverage

14-Sep-2020

Trinity Delta Research Report Published

Analyst reports

09-Sep-2020

Redx announces new research collaboration with Jazz Pharmaceuticals to discover and develop two targeted cancer therapies

Press release

20-Aug-2020

Further information regarding the offer to purchase shares by Redmile Group LLC

Press release

05-Aug-2020

Appointment of Non-Executive Director and changes to Board committees

Press release

04-Aug-2020

Redx signs out licensing agreement with AstraZeneca

Press release

20-Jul-2020

Result of General Meeting

Press release

30-Jun-2020

Proposed financing of $30 million via issue of convertible loan notes and share subscription and notice of General Meeting

Press release

30-Jun-2020

Interim results for the six months ended 31 March 2020

Press release

30-Jun-2020

New All Employee Share Option Scheme and Grant of Options

Press release

02-Jun-2020

Redx Pharma PLC’s Lisa Anson updates on lead asset RXC004 and increased investment by Redmile

Media coverage

20-May-2020

Change of Adviser

Press release

18-May-2020

Appointment of Non-Executive Director with Deep Experience of the Biotechnology Industry and Capital Markets

Press release

23-Apr-2020

Result of Annual General Meeting and operational update

Press release

31-Mar-2020

Further information for shareholders regarding attendance at the Company’s Annual General Meeting on 23 April 2020

Press release

30-Mar-2020

Redx Redmile Loan announcement

Press release

11-Mar-2020

Final Audited Results for the Year Ended 30 September 2019 and operational update

Press release

28-Feb-2020

Redx agrees funding from Redmile Group, LLC & Sofinnova Partners

Press release

28-Feb-2020

Termination of discussions with Yesod Bio-Sciences Limited (“Yesod”)

Press release

14-Feb-2020

Further statement re Rule 2.6 Extension 14 Feb 2020

Press release

28-Jan-2020

Statement re Rule 2.6 Extension

Press release

23-Jan-2020

Result of General Meeting

Press release

09-Jan-2020

Redx Pharma nominates RXC007, a novel, orally active ROCK2 inhibitor as next drug development candidate in fibrosis

Press release

03-Jan-2020

Shareholder Circular – Proposed Capitalisation of Loan

Press release

31-Dec-2019

Redx Pharma plc – Loan Capitalisation, GM Notice and Possible Offer

Press release

19-Nov-2019

Redx Pharma and Medicines Discovery Catapult awarded grant for biomarker project which aims to accelerate therapeutic development for idiopathic pulmonary fibrosis

Press release

23-Sep-2019

Poster presentation at ERS Congress highlights RXC006 as a novel and promising drug candidate for the treatment of idiopathic pulmonary fibrosis (IPF)

Press release

20-Aug-2019

Video interview with Lisa Anson following news of first cohort of patients successfully dosed with RXC004 in Phase 1/2 Study

Media coverage

19-Aug-2019

First Cohort of Patients Successfully Dosed in RXC004 Phase 1/2 Study; Second Cohort Enrolment Has Now Begun

Press release

11-Jul-2019

Video interview with Lisa Anson following sale of pan-RAF inhibitor programme to Jazz Pharmaceuticals

Media coverage

10-Jul-2019

Redx announces sale of its pan-RAF inhibitor programme to Jazz Pharmaceuticals

Press release

13-Jun-2019

Video interview with Lisa Anson following Interim Results confirming start of phase I study of lead drug RXC004

Media coverage

10-Jun-2019

Interim Results for the six months ended 31 March 2019

Press release

10-Jun-2019

Short-term Debt Funding Secured

Press release

03-May-2019

Update on Plans to Strengthen Balance Sheet

Press release

29-Mar-2019

Redx Pharma to present two posters at the 2019 American Association for Cancer Research (AACR) Annual Meeting

Press release

19-Mar-2019

Redx Pharma CEO Lisa Anson appears in the Telegraph’s International Women’s Day feature

Media coverage

28-Feb-2019

Issue of Warrants and Change to Lease Agreement

Press release

14-Feb-2019

Redx announces directorate update and grant of options

Press release

13-Feb-2019

Lisa Anson talks about new in vivo data indicating the broad potential of ROCK2 inhibitor in fibrosis (Video)

Media coverage

12-Feb-2019

New in vivo data suggests ROCK2 has broad potential in fibrosis

Press release

06-Feb-2019

Redx confirms receipt of outstanding loan

Press release

31-Jan-2019

Deinove return rights to Redx’s Anti-infective Programme

Press release

23-Jan-2019

Results of Annual General Meeting

Press release

22-Jan-2019

Redx Pharma receives approval to re-commence clinical trial of RXC004 (Proactiveinvestors.co.uk)

Media coverage

21-Jan-2019

Redx to resume RXC004 clinical trial programme

Press release

03-Jan-2019

Redx to present at 2019 Biotech Showcase event in San Francisco

Press release

02-Jan-2019

Annual Report and Accounts for the year ended 30 September 2018

Press release

30-Nov-2018

First RXC006 data suggests it has great potential for the treatment of fibrosis

Press release

23-Nov-2018

CSO Richard Armer outlines development ambitions and clinical targets (Video)

Media coverage

19-Nov-2018

Final Audited Results for the Year Ended 30 September 2018

Press release

19-Nov-2018

Redx further strengthens Management Team and Board with appointment of Dr James Mead as CFO

Press release

14-Nov-2018

Redx Pharma announces new drug development candidate for fibrosis

Press release

05-Nov-2018

Preclinical data evaluating RXC004 presented at the NCRI cancer conference

Press release

31-Oct-2018

Preliminary Results – Analysts’ Meeting and Webcast on Monday, 19 November 2018

Press release

31-Oct-2018

Notice of Results

Press release

29-Oct-2018

REDX Pharma notes election of Lisa Anson to UK BIA Board of Directors

Press release

26-Oct-2018

Redx announces details from the ROCK2 inhibitor poster presented at the ASN Kidney Week 2018 in San Diego

Press release

22-Oct-2018

Redx ROCK2 inhibitors poster to be presented at the ASN Kidney Week 2018 in San Diego

Press release

04-Sep-2018

Redx Pharma Announces Way Forward For RXC004

Press release

04-Jun-2018

Directorate Update and Grant of Options

Press release

30-May-2018

Interim Results Announced

Press release

24-Apr-2018

Redx Appoints Senior AstraZeneca Executive as CEO

Press release

29-Mar-2018

RXC004 Clinical Trial Update

Press release

22-Mar-2018

Redx Pharma signs option and licence agreement for its anti-infective programme with Deinove

Press release

15-Mar-2018

Redx Pharma to present poster at prestigious American Association for Cancer Research Annual Meeting

Press release

06-Feb-2018

Redx Pharma Announces First Patient Dosed in Phase 1/2a

Press release

22-Jan-2018

Redx Pharma appoints chief medical officer who will oversee launch of phase I clinical trial of new cancer drug

Press release

20-Dec-2017

Final Results for the Year Ended 30 September 2017

Press release

06-Nov-2017

Redx Provides a Strategic Update and Announces that Trading is to recommence in its Shares

Press release

02-Nov-2017

The Joint Administrators’ Final Report for the period 24 May 2017 to 2 November 2017

Press release

13-Oct-2017

Permission granted for distribution to Unsecured Creditors

Press release

31-Aug-2017

Redx to present new scientific data at ESMO 2017

Press release

24-May-2017

In Administration

Press release

17-May-2017

Interim Results for the six months ended 31 March 2017

Press release

15-May-2017

Preclinical data for reversible BTK inhibitor RXC005 presented at the 17th International Workshop of Chronic Lymphocytic Leukemia

Press release

20-Apr-2017

Appointment of Chairman

Press release

10-Apr-2017

Redx Pharma presents data in oncology and fibrosis at two key scientific congresses

Press release

30-Mar-2017

Redx Pharma awarded US$1 million grant by CARB-X

Press release

21-Mar-2017

Final Results for the year ended 30 September 2016

Press release

03-Mar-2017

Redx to present new scientific data at AACR 2017

Press release

02-Mar-2017

Nationwide search begins for science’s inspirational business leaders

Press release

27-Jan-2017

Redx outlines growing opportunity for Porcupine inhibitors

Press release

06-Dec-2016

Pre-clinical profile of reversible BTK inhibitor RXC005 presented at ASH 2016

Press release

30-Nov-2016

Pre-clinical profile of Porcupine inhibitor RXC004 presented at EORTC-NCI-AACR 2016

Press release

14-Nov-2016

Redx Pharma in the running for prestigious North of England awards

Press release

10-Nov-2016

Redx backs global AMR event

Press release

04-Nov-2016

Redx to present pre-clinical profile of its reversible BTK inhibitor at ASH 2016

Press release

25-Oct-2016

Redx supports young scientists in Staffordshire University’s GradEX exhibition

Press release

25-Oct-2016

Redx to present Preclinical Data on Novel Bacterial Topoisomerase Inhibitors at ASM Microbe 2016 Conference

Press release

20-Oct-2016

Development candidate chosen for leukaemia program

Press release

27-Sep-2016

Discovery of breakthrough antibiotic compounds

Press release

19-Sep-2016

Redx confirms potential role for Porcupine inhibitor in cancer immunotherapy

Press release

08-Sep-2016

Board and Senior Management Changes

Press release

06-Sep-2016

Supply contract agreed with Quay Pharma for expected clinical trial of Porcupine inhibitor

Press release

10-Jun-2016

Redx backs North of England biotech focus

Press release

06-Jun-2016

World leaders in biotech to hear from Northern Powerhouse

Press release

24-May-2016

Interim Results

Press release

24-May-2016

Proof of concept with key oncology lead

Press release

19-May-2016

O’Neill signs off with powerful plan to tackle superbugs

Press release

09-May-2016

Board appointment

Press release

16-Apr-2016

Redx Pharma to present at the Annual Meeting of the American Association for Cancer Research (AACR) in New Orleans on 20 April

Press release

14-Apr-2016

Redx Pharma Plc set for new HQ at Alderley Park

Press release

12-Apr-2016

Redx backs key AMR conference

Press release

24-Mar-2016

Placing to Raise £10 Million

Press release

26-Feb-2016

Redx honoured at Institute of Directors Awards

Press release

24-Feb-2016

AGM Statement – Sixth proof of concept – Potential new treatment for gonorrhoea

Press release

03-Feb-2016

World Cancer Day 2016

Press release

21-Jan-2016

Redx joins global pharma call on governments to help tackle AMR crisis

Press release

20-Jan-2016

Final Results for the year ended 30 September 2015

Press release

01-Jan-2016

Appointment of Non-Executive Director

Press release

03-Dec-2015

Redx Pharma announces fourth drug development candidate

Press release

27-Nov-2015

Redx Pharma wins Deal of the Year at Bionow Awards

Press release

10-Nov-2015

BioInfect Conference – Redx joins industry leaders to combat one of the biggest threats to global health

Press release

05-Nov-2015

Senior management appointments

Press release

28-Oct-2015

Millions of wasted prescriptions adding to superbug threat, warns O’Neill

Press release

01-Oct-2015

Year-end trading update

Press release

03-Sep-2015

Cancer research collaboration with Horizon Discovery Group plc

Press release

13-Jul-2015

Chancellor visits Redx labs

Press release

07-Jul-2015

LSE visit to Alderley Park site

Press release

22-Jun-2015

Interim Results For The Six Months Ended 31 March 2015

Press release

02-Jun-2015

Discovery of breakthrough MRSA compound

Press release

26-May-2015

Redx announces second drug development candidate

Press release

14-May-2015

Launch of third subsidiary, Redx Immunology Limited

Press release

11-May-2015

Redx reaches pre-clinical proof of concept with Oncology lead

Press release

05-Feb-2015

Redx Pharma featured in BBC Report on drug-resistant infections

Press release

11-Dec-2014

Redx features at key AMR Review

Press release

18-Nov-2014

European Antibiotic Awareness Day 2014

Press release

18-Nov-2014

Antibiotic Guardian – European Antibiotic Awareness Day

Press release

05-Nov-2014

Redx joins call to discover new antibiotics to stop global crisis

Press release

15-Oct-2014

Redx Pharma focuses on human health with agrichem deal

Press release

12-Sep-2014

Redx Pharma strengthens senior team

Press release

03-Sep-2014

Redx Pharma and AstraZeneca agree research collaboration targeting genetic drivers of tumour growth

Press release

01-Sep-2014

Redx Pharma appoints new chairman

Press release

20-Jun-2014

International Festival For Business 2014

Press release

06-Mar-2014

Redx Pharma and Pierre Fabre collaborate in the promising field of Onco-Dermatology

Press release

12-Feb-2014

€85 million European program targets novel antibiotics

Press release

30-Nov-2013

Redx Pharma addresses flagship antibiotic conference

Press release

29-Nov-2013

Redx Pharma named Bionow Company of the Year 2013

Press release

26-Nov-2013

Redx Pharma co-sponsors BioInfect 2013

Press release

07-Nov-2013

Redx agrees pioneering MRSA deal with NHS

Press release

14-Oct-2013

Health leaders gather to tackle ‘Antibiotic Apocalypse’

Press release

11-Oct-2013

Redx CEO scoops business leadership award

Press release

10-Sep-2013

BIA welcomes the publication of the UK government antimicrobial resistance strategy (AMR) that drives to put the challenge of AMR on the global agenda

Press release

29-Jul-2013

Redx Oncology enters agreement to support Liverpool tissue bank

Press release

12-Jul-2013

RGF backing for proposed Redx Metabolic venture

Press release

14-Jun-2013

Knowledge Business of the Year 2013

Press release

07-May-2013

Redx Pharma opens £10.5 million R&D centre at Alderley Park

Press release

02-May-2013

Redx Pharma and Pharmascience enter into license agreement for cFMS cancer program

Press release

13-Mar-2013

Antibiotic Resistance – Dr Neil Murray, CEO Redx Pharma

Press release

14-Jan-2013

Redx Oncology staff dig deep to raise funds for Liverpool Cancer Research UK Centre

Press release

02-Jan-2013

Redx Oncology continues to experience dramatic growth

Press release